15 million cancer patients suffer from depression and anxiety in North America and Europe.
Patients need rapid access to safe and effective mental health treatments – we design and develop next-generation psychotherapeutics.
Are you an Albert Labs Investor yet?
We have an open financing round seeking gross proceeds of CA$3,000,000, with the first tranche (CS$500,000) offered at $0.08/Unit.
80% of our upcoming clinical trials has funding in place, including a cash rebate for an estimated CA$1.2 million from the Australian Government and a CA$830,000 strategic investment from Cantheon Capital LLC.
Our First In-Human studies on our IP protected, psilocybin-based medicine, KRN-101, are due to commence in Q3 2023 in partnership with leading Contract Research Organization, iNGENu.
Value Creation from Proceeds:
Toxicology and First In-Human trials in 2023
Clinical Trial Application for its late-stage Real World Evidence trial in the United Kingdom (MHRA)
IND filing (FDA)
Interested in learning more?
Each Unit is comprised of one common share (the “Common Share”) and one-half of one whole Common Share purchase warrant (each whole warrant, a “Warrant”) with each whole Warrant entitling the holder to purchase one additional Common Share of the Company at a price of CAD $0.12 per Share for a period of 12 months from the date of issuance. In the event that the Company’s common shares have a closing price on the CSE of greater than CAD $0.15 per common share for a period of 10 consecutive trading days, the Company may accelerate the expiry date of the Warrants by giving notice to the holders thereof and, in such case, the Warrants will expire on the 30th day after the date on which such notice is given to the holder by the Company.
All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation.
Our people bring experience and expertise across multiple domains to deliver a scalable, effective, solution to the mental health crisis.
“The life sciences industry are well aware of the significant gap that still remains in alleviating related mental health distress”
“Psychedelic therapy heals people. Thats really not something I’ve seen us do in psychiatry in all my career”
“I value Albert Labs’ emphasis on ethical and patient-centred investigations of the effectiveness of psychotherapy and psilocybin. ”
“It is an extremely exciting time for Albert Labs, we’re looking forward to treating our first patients with our product.”
© 2023 Albert Labs. All Rights Reserved
Our people bring experience and expertise across multiple fields to deliver a scalable solution to the mental health crisis.
We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.
If you would like support or more information around making an investment, please contact [email protected]